title: Impact of dronedarone in atrial fibrillation and flutter on stroke reduction.
abstract: BACKGROUND
  Dronedarone has been developed for treatment of atrial fibrillation (AF) or atrial flutter (AFL). It is an amiodarone analogue but noniodinized and without the same adverse effects as amiodarone.
  
  
  OBJECTIVE
  This is a review of 7 studies (DAFNE, ADONIS, EURIDIS, ATHENA, ANDROMEDA, ERATO and DIONYSOS) on dronedarone focusing on efficacy, safety and prevention of stroke. There was a dose-finding study (DAFNE), 3 studies focusing on maintenance of sinus rhythm (ADONIS, EURIDIS and DIONYSOS), 1 study focusing on rate control (ERATO) and 2 studies investigating mortality and morbidity (ANDROMEDA and ATHENA).
  
  
  RESULTS
  The target dose for dronedarone was established in the DAFNE study to be 400 mg twice daily. Both EURIDIS and ADONIS studies demonstrated that dronedarone was superior to placebo for maintaining sinus rhythm. However, DIONYSOS found that dronedarone is less efficient at maintaining sinus rhythm than amiodarone. ERATO concluded that dronedarone reduces ventricular rate in patients with chronic AF. The ANDROMEDA study in patients with severe heart failure was discontinued because of increased mortality in dronedarone group. Dronedarone reduced cardiovascular hospitalizations and mortality in patients with AF or AFL in the ATHENA trial. Secondly, according to a post hoc analysis a significant reduction in stroke was observed (annual rate 1.2% on dronedarone vs 1.8% on placebo, respectively [hazard ratio 0.66, confidence interval 0.46 to 0.96, P = 0.027]). In total, 54 cases of stroke occurred in 3439 patients (crude rate 1.6%) receiving dronedarone compared to 76 strokes in 3048 patients on placebo (crude rate 2.5%), respectively.
  
  
  CONCLUSIONS
  Dronedarone can be used for maintenance of sinus rhythm and can reduce stroke in patients with AF who receive usual care, which includes antithrombotic therapy and heart rate control.
authors.affiliation: Department of Cardiology, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark;
authors.forename: Christine Benn
authors.initials: CB
authors.lastname: Christiansen
authors.forename: Christian
authors.initials: C
authors.lastname: Torp-Pedersen
authors.forename: Lars
authors.initials: L
authors.lastname: Køber
mesh_terms: D000638:Amiodarone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D000077764:Dronedarone; D006801:Humans; D020521:Stroke / Q000517:prevention & control*
chemical_list: D000889:Anti-Arrhythmia Agents; D000077764:Dronedarone; D000638:Amiodarone
references.citation: Lancet. 1997 May 3;349(9061):1269-76
references.pmid: 9142060
references.citation: N Engl J Med. 2008 Jun 19;358(25):2678-87
references.pmid: 18565860
references.citation: J Cardiovasc Pharmacol. 2003 Feb;41(2):191-202
references.pmid: 12548079
references.citation: Br J Clin Pharmacol. 2007 Dec;64(6):785-91
references.pmid: 17662087
references.citation: Lancet. 1992 Feb 8;339(8789):342-4
references.pmid: 1346420
references.citation: J Cardiovasc Pharmacol. 2000 Dec;36(6):802-5
references.pmid: 11117382
references.citation: Circulation. 1991 Aug;84(2):527-39
references.pmid: 1860198
references.citation: Stroke. 1991 Aug;22(8):983-8
references.pmid: 1866765
references.citation: Am Heart J. 2008 Sep;156(3):527.e1-9
references.pmid: 18760136
references.citation: Arch Intern Med. 2005 May 23;165(10):1185-91
references.pmid: 15911734
references.citation: Circulation. 2009 Sep 29;120(13):1174-80
references.pmid: 19752319
references.citation: N Engl J Med. 2007 Sep 6;357(10):987-99
references.pmid: 17804843
references.citation: Arch Intern Med. 2005 Feb 14;165(3):258-62
references.pmid: 15710787
references.citation: Eur Heart J. 2003 Aug;24(16):1481-7
references.pmid: 12919771
references.citation: Br J Pharmacol. 1995 Oct;116(3):1949-56
references.pmid: 8640331
references.citation: N Engl J Med. 1990 Nov 29;323(22):1505-11
references.pmid: 2233931
references.citation: N Engl J Med. 2009 Apr 30;360(18):1811-3
references.pmid: 19403901
references.citation: J Am Coll Cardiol. 2009 Sep 15;54(12):1089-95
references.pmid: 19744618